Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,133 public trials 2,035 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Active, not recruiting

Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes

NCT06282978

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Hospital Clínico Universitario de Santiago ~ CHUS Santiago de Compostela, A Coruña, Spain
  • Hospital Son Llàtzer Palma de Mallorca, Balearic Islands, Spain
  • Institut Catala d'Oncologia (ICO) Badalona - Hospital Universitari Germans Trias i Pujol Badalona, Barcelona, Spain
  • Hospital Universitario Marqués de Valdecilla Santander, Cantabria, Spain
View all 13 locations
View Trial Details
Active, not recruiting

Study of Lacutamab in Peripheral T-cell Lymphoma

NCT04984837

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +14 more
Locations
  • Institut Jules Bordet Anderlecht, Belgium
  • VZW ZAS Antwerp, Belgium
  • A. Z. Sint-Jan Bruges, Belgium
  • Cliniques Universitaires de Bruxelles - Hôpital Erasme Brussels, Belgium
View all 64 locations
View Trial Details
Active, not recruiting

Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

NCT03960840

Conditions
Acute Lymphoblastic Leukemia, Chronic Disease, Chronic Lymphocytic Leukemia, +23 more
Locations
  • University of California LA Los Angeles, California, United States
  • Stanford University Medical Center Stanford, California, United States
  • H Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States
  • Uni of Chi Medi Ctr Hema and Onco Chicago, Illinois, United States
View all 37 locations
View Trial Details
Active, not recruiting

KRDI in Transplant-Eligible MM

NCT04430894

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
View Trial Details
Active, not recruiting

Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

NCT01415752

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
  • Alaska Women's Cancer Care Anchorage, Alaska, United States
  • Anchorage Oncology Centre Anchorage, Alaska, United States
  • Katmai Oncology Group Anchorage, Alaska, United States
View all 418 locations
View Trial Details
Active, not recruiting

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

NCT02101853

Conditions
Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +15 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • USA Health Strada Patient Care Center Mobile, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
View all 186 locations
View Trial Details

Related conditions